banner
 
bar

program

slides
bar
 
 

Complementary Basal Insulin Plus Incretin System-Targeted Agents in Challenging Patients with Diabetes

WebCAST

pre-program survey
We Invite You to Take a Moment and Complete This
Pre-Program Knowledge and Clinical Performance Survey.
Thank You
Viewer Survey
How long did you spend on this program?

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium

Internet-based program

Estimated Time to Complete Educational Activity

2.5 hours

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of advances in the management of diabetes.

Release Date

June 23, 2016

Expiration Date

June 23, 2018

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period June 23, 2016 through June 23, 2018, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 9 segments totaling 2.5 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.

Registration

Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

Supported by an educational grant from Sanofi Diabetes.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and CMEducation Resources, LLC. 'The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Massachusetts Medical School designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Committee/Staff Disclosure

The following CMEducation Resources planners and managers, Gideon Bosker and Milo Falcom, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Program Faculty and Disclosure

VIVIAN A. FONSECA, MD, FRCP
(Program Chair)

Professor of Medicine and Pharmacology
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, LA

Research Support (to Tulane): Novo Nordisk, Asahi, Eli Lilly, Abbott, Endo Barrier, Gilead Sciences
Honoraria for Consulting and Lectures: Takeda, Novo Nordisk, Sanofi-Aventis, Eli Lilly, Pamlabs, AstraZeneca, Abbott, Amgen, Boehringer Ingelheim, Janssen



LAWRENCE A. LEITER, MD, FRCP(C), FACP
Professor
Departments of Medicine and Nutritional Sciences
University of Toronto
Director, Lipid Clinic
St. Michael’s Hospital
Toronto, Canada

Consulting: Astra Zeneca, BI, Eli Lilly, Janssen, Merck, Novo Nordisk, Sanofi, Servier
Speakers Bureau: Astra Zeneca, BI, Eli Lilly, Janssen, Merck, Novo Nordisk, Sanofi
Contracted Research: Astra Zeneca, BI, Eli Lilly, GSK, Janssen, Merck,
Novo Nordisk, Pfizer, Sanofi, Servier



CHARLES F. SHAEFER JR., MD, FACP
Assistant Clinical Professor of Medicine
Medical College of Georgia at Augusta University
Senior Partner
University Medical Group, University Health Systems
Augusta, Georgia

Consulting Fees: Sanofi, Lilly, Astra Zeneca, Janssen, Genzyme
Speaker’s Bureau: Sanofi, Lilly, Astra Zeneca, BI
Contracted Research: Sanofi, Adocia



JUAN P. FRIAS, MD, FACE
Clinical Assistant Professor of Medicine
University of California, San Diego
President
National Research Institute
Los Angeles, CA

Consulting Fees: Johnson and Johnson, Astra Zeneca, CeQur
Contracted Research: Astra Zeneca, Boehringer Ingelheim, BMS, Lilly, Novo Nordisk, Merck, Pfizer, Sanofi, Takeda, Theracos, Janssen, vTv, IONIS, Pfizer

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Explain the physiologic basis for when, why, and in which patients subgroups basal insulin in combination with a short-acting GLP-1 RA is appropriate in patients with diabetes; and how fixed dose combinations therapies employing a GLP-1 RA and basal insulin can provide complementary efficacy, especially in patients with postprandial hyperglycemia;
  • Describe the foundational role of basal insulins, especially those that mimic physiologic properties of endogenous insulin, as part of a multimodal treatment roadmap for diabetes management in the primary care setting;
  • Combine basal insulin with complementary agents such as GLP-1 agonists to treat FPG and PPG in patients with T2D managed in the primary care setting;
  • List the unique safety, compliance and target goal needs for the diabetic patients managed in the primary care setting, and the rationale for sequencing and combining anti-glycemic therapies based on physiologic needs addressing the full range of hyperglycemic dysregulation;
  • Deploy combination therapeutic regimens—including GLP-1 agonists in combination with basal insulin, and OADs—that, in an individualized manner, optimize HA1c target goal attainment as outlined in the Year 2015 ADA/EASD Guidelines and Recommendations for T2D Management;

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Copyright © 2016 by CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.
Copyright © CMEducation Resources, LLC

bar

program

slides
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © CMEducation Resources, LLC

 
6

 

Key Program Topics Include:

A1c
AACE
AACE/ACE
ACCORD
ADA
ADA/EASD
ADVANCE
Alpha glucosidase inhibitors
Amylin mimetics
Antihyperglycemic
Basal Insulin
biguanides
Biguanides
Bile acid sequentrants
Dapagliflozin
DCCT
Diabetes Dopamine 2 agonists
DPP-4 inhibitor

DPP4 inhibitors
Dyslipidemia
ESRD
Exenatide
FPG
Glargine
Gliclazide
glimiperide
Glomerulus
GLP agonist
GLP1 receptor agonists
Glucose
GLUT2
glyburide
Glycemia
Glycemic
Glycogenolysis
HbA1c

 

HDL
Homeostasis
SGLT2
Hypertension
Hypoglycemia
Hypoglycemia
incretin
Insulin
Insulin detemir
insulinopenia
Kidney
LDL
Meglitines
Metformin
Microalbumin
NHANES
NPH Obesity
Type 2
Pioglitazone

PPG
prandial
PREMIX
PROACTIVE
SGLT1
Sodium-Glucose Cotransporters
Sulfonlyureas
Sulfonylureas
T2D
T2DM
Thiazolidinedione
troglitazone
TZD
UKPDS
VADT
U300
U100